These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 29476612)

  • 1. Prognostic performance of serial in-hospital measurements of copeptin and multiple novel biomarkers among patients with worsening heart failure: results from the MOLITOR study.
    Düngen HD; Tscholl V; Obradovic D; Radenovic S; Matic D; Musial Bright L; Tahirovic E; Marx A; Inkrot S; Hashemi D; Veskovic J; Apostolovic S; von Haehling S; Doehner W; Cvetinovic N; Lainscak M; Pieske B; Edelmann F; Trippel T; Loncar G
    ESC Heart Fail; 2018 Apr; 5(2):288-296. PubMed ID: 29476612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
    Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
    Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
    Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
    J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study.
    Charitakis E; Walfridsson H; Alehagen U
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular biomarkers predict post-discharge re-hospitalization risk and mortality among Swedish heart failure patients.
    Molvin J; Jujic A; Bachus E; Gallo W; Tasevska-Dinevska G; Holm H; Melander O; Fedorowski A; Magnusson M
    ESC Heart Fail; 2019 Oct; 6(5):992-999. PubMed ID: 31339668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
    Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
    Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality.
    Pavo N; Raderer M; Hülsmann M; Neuhold S; Adlbrecht C; Strunk G; Goliasch G; Gisslinger H; Steger GG; Hejna M; Köstler W; Zöchbauer-Müller S; Marosi C; Kornek G; Auerbach L; Schneider S; Parschalk B; Scheithauer W; Pirker R; Drach J; Zielinski C; Pacher R
    Heart; 2015 Dec; 101(23):1874-80. PubMed ID: 26416836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy.
    Arrigo M; Truong QA; Szymonifka J; Rivas-Lasarte M; Tolppanen H; Sadoune M; Gayat E; Cohen-Solal A; Ruschitzka F; Januzzi JL; Singh JP; Mebazaa A
    Europace; 2017 Nov; 19(11):1848-1854. PubMed ID: 28096288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study.
    Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C
    Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress.
    Sinning C; Ojeda F; Zeller T; Zengin E; Rupprecht HJ; Lackner KJ; Bickel C; Blankenberg S; Schnabel RB; Westermann D
    Can J Cardiol; 2016 Dec; 32(12):1470-1477. PubMed ID: 27568502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and diagnostic significance of mid-regional pro-atrial natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 Study.
    Pervez MO; Winther JA; Brynildsen J; Strand H; Christensen G; Høiseth AD; Myhre PL; Røysland R; Lyngbakken MN; Omland T; Røsjø H
    Biomarkers; 2018 Nov; 23(7):654-663. PubMed ID: 29733687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH.
    Kolditz M; Seyfarth HJ; Wilkens H; Ewert R; Bollmann T; Dinter C; Hertel S; Klose H; Opitz C; Grünig E; Höffken G; Halank M
    Lung; 2015 Dec; 193(6):901-10. PubMed ID: 26363916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD.
    Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M
    Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249
    [No Abstract]   [Full Text] [Related]  

  • 14. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
    Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
    Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
    Bégué C; Mörner S; Brito D; Hengstenberg C; Cleland JGF; Arbustini E; Galve E; Wichter T; Richter A; Golmard JL; Bernard M; Dubourg O; Komajda M; Charron P; Isnard R
    Heart; 2020 Feb; 106(3):196-202. PubMed ID: 31350276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Stages of Obesity-related Heart Failure Are Associated with Natriuretic Peptide Deficiency and an Overall Lack of Neurohormonal Activation: The Copenhagen Heart Failure Risk Study.
    Gaborit FS; Kistorp C; Kümler T; Hassager C; Tønder N; Iversen K; Kamstrup PR; Faber J; Køber L; Schou M
    Glob Heart; 2020 Mar; 15(1):25. PubMed ID: 32489798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure.
    Arfsten H; Bartko PE; Pavo N; Heitzinger G; Mascherbauer J; Hengstenberg C; Hülsmann M; Goliasch G
    Eur J Clin Invest; 2019 Nov; 49(11):e13159. PubMed ID: 31356682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure.
    Miller WL; Hartman KA; Grill DE; Struck J; Bergmann A; Jaffe AS
    Heart; 2012 Mar; 98(5):389-94. PubMed ID: 22194151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mid-regional pro-adrenomedullin in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
    Pervez MO; Lyngbakken MN; Myhre PL; Brynildsen J; Langsjøen EC; Høiseth AD; Christensen G; Omland T; Røsjø H
    Clin Biochem; 2017 May; 50(7-8):394-400. PubMed ID: 28065681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
    Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
    J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.